Search

everythinglearnresearchcommunity

for

Search:↓

GT20029 is anticipated to start phase III trials in Q3 2026, with potential public availability around 2029-2030.

The conversation discusses organizing group buys and tracking progress for Kx-826 Pyrilutamide, a hair loss treatment. Participants express optimism about upcoming results and concerns about self-reporting bias.

Scientists discover SCUBE3 molecule for potential baldness cure. Mice used in research for hair growth signaling.

The conversation is about the potential benefits of Rapamycin for hair pigmentation and regeneration, based on effects observed in mice. The original poster is seeking personal experiences from others using Rapamycin for longevity.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Anageninc stopped selling KX-826 (Pyrilutamide) due to a cease and desist letter from Kintor, but this may indicate promising study results and a potential 2024 release.

User asks if HMI 115 hasn't done phase 1 for AGA in humans. Conversation includes treatments Min, Fin, and RU.

A user who has seen positive results after 7 years of treating their hair loss with Rogaine, Nizoral Shampoo, and finasteride. Other users have also shared advice about micro-needling in combination with minoxidil.

RT1640, a combination of cyclosporin A, minoxidil, and RT175, is discussed as a potential treatment for hair regrowth and repigmentation. The unique formulation aims to enhance hair follicle growth and restore hair pigment without the negative side effects of immunosuppressants.

The conversation discusses the approval of Kintor Pharmaceutical's AR-PROTAC (GT20029) for clinical trials in China for acne and androgenic alopecia. One user expresses optimism about new treatments being developed and seeks clarification on how the new drug works, specifically if it temporarily degrades the AR protein to reduce DHT sensitivity in hair follicles.

The conversation discusses switching from RU58841 to pyrilutamide for hair loss treatment, with users generally recommending staying on RU58841 if it is effective. RU58841 is sourced from GeneTherica, which ships worldwide.

A 27-year-old user shared their 7-week progress using topical finasteride 0.3% and minoxidil 6% daily, along with keto 2% shampoo twice a week and derma needling every 2-3 weeks. They reported no side effects.

A user's father experienced hair regrowth and other health improvements after two IV exosome treatments. The user also had four rounds of exosome therapy, noting significant hair regrowth and relief from headaches, but no change in gray hair.

The conversation is about the difficulty in obtaining GT20029, a hair loss treatment, due to patent issues and the need to resort to group buys or Chinese labs for acquisition. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

RU58841 solution developed crystals after refrigeration. Letting it reach room temperature and shaking can dissolve the crystals.

A user shared their 7-month progress using Minoxidil and Finasteride for hair loss, which significantly reversed their aging appearance. They applied Minoxidil twice daily, took 1mg Finasteride once daily, micro-needled weekly, maintained a high protein diet with vitamins and biotin, and recommended a balanced lifestyle for best results.

The user has been using finasteride (1.25mg) for 21 months and oral minoxidil (2.5mg) for 7 months with no noticeable improvement, seeking others' experiences on timelines for results. Suggestions include microneedling and vitamin D supplements, with the expectation that modest results or maintenance are common.

A 16-year-old researching and trying Pyrilutamide for hair loss treatment, reporting back on side effects experienced after one week of use; the reported side effects included testicle pain, headache, and increased shedding. Libido and sexual performance seemed unaffected.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

A user is attempting to recover from severe hair loss using 1.25mg finasteride, 5mg topical minoxidil twice daily, pyrilutamide for a month, RU58841 for two weeks, and weekly microneedling at 1.5mm. They have seen new hair growth after two months and plan to continue the treatment for a year with the hope of regrowing enough hair for a transplant.

The conversation discusses the potential of a new hair loss treatment, GT20029, which may prevent hair loss by destroying androgen receptors on the scalp. Users express hope for the treatment's success and speculate on its usage routine, effectiveness, and possible side effects.

After 7 months of a hair transplant, the user is experiencing significant hair loss despite using a minoxidil and finasteride topical solution daily. Losing around 100 hairs daily might be normal, but if it persists, other causes should be considered.

GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.

The user is happy with hair regrowth after 7 months using a topical spray containing 6% minoxidil and 0.3% finasteride from Hims, experiencing no side effects. They noticed significant results around 3-4 months and find the treatment convenient and cost-effective.

The conversation is about the potential impact of RU58841 on male fertility, specifically regarding sperm concentration, total count, and motility. The user is curious about the likelihood of RU58841 reducing fertility based on its mechanism of action and comparisons to similar substances.

Shiseido RCH-01 and Replicel's upcoming trial data release. Users discuss expected release timelines and clarify quarter dates.

Hope Medicine's announcement of the HMI-115 Phase II clinical trial for androgenetic alopecia in China; other related trials have been conducted or are ongoing in different countries, including Australia, US, and Europe. There is speculation that the product may be accepted across borders without additional testing.

A 32-year-old man from Vietnam, at Norwood 7 hair loss, is using Minoxidil, Finasteride, rosemary oil, NMN, and CoQ10 to regrow hair. Despite minor improvements, alternatives like hair systems or accepting baldness are suggested due to advanced hair loss.

The user shared their hair loss treatment progress using oral and topical dutasteride, topical minoxidil, microneedling, and keto shampoo. They plan to possibly add LLLT, PRP with exosomes, and other treatments in the future.

The user is pleased with their hair transplant results after six months and seeks feedback. The conversation is positive, with others affirming the success of the procedure.

A six month update of the users' experience with Pyrilutamide, a hair loss treatment that combines Minoxidil, Finasteride and RU58841.